CA2388474A1 - Vasopressin antagonist formulation and process - Google Patents

Vasopressin antagonist formulation and process Download PDF

Info

Publication number
CA2388474A1
CA2388474A1 CA002388474A CA2388474A CA2388474A1 CA 2388474 A1 CA2388474 A1 CA 2388474A1 CA 002388474 A CA002388474 A CA 002388474A CA 2388474 A CA2388474 A CA 2388474A CA 2388474 A1 CA2388474 A1 CA 2388474A1
Authority
CA
Canada
Prior art keywords
component
pharmaceutical composition
polysorbate
weight
polyethylene glycols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388474A
Other languages
English (en)
French (fr)
Inventor
Mahdi Bakir Fawzi
Joseph Kyuwung Yoon
Richard William Saunders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388474A1 publication Critical patent/CA2388474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002388474A 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process Abandoned CA2388474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
US09/405,772 1999-09-27
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Publications (1)

Publication Number Publication Date
CA2388474A1 true CA2388474A1 (en) 2001-04-05

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388474A Abandoned CA2388474A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Country Status (18)

Country Link
EP (1) EP1216033A1 (ja)
JP (1) JP2003510269A (ja)
KR (1) KR20020039354A (ja)
CN (1) CN1391466A (ja)
AR (1) AR025780A1 (ja)
AU (1) AU7615000A (ja)
BR (1) BR0014351A (ja)
CA (1) CA2388474A1 (ja)
CZ (1) CZ20021083A3 (ja)
EA (1) EA200200414A1 (ja)
HK (1) HK1045109A1 (ja)
HU (1) HUP0202972A3 (ja)
IL (1) IL148541A0 (ja)
MX (1) MXPA02003189A (ja)
NO (1) NO20021475L (ja)
PL (1) PL354282A1 (ja)
WO (1) WO2001022945A1 (ja)
ZA (1) ZA200203312B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
MXPA02003189A (es) 2002-09-30
KR20020039354A (ko) 2002-05-25
IL148541A0 (en) 2002-09-12
EP1216033A1 (en) 2002-06-26
CZ20021083A3 (cs) 2002-06-12
HUP0202972A2 (hu) 2002-12-28
AR025780A1 (es) 2002-12-11
HUP0202972A3 (en) 2003-07-28
ZA200203312B (en) 2003-12-31
WO2001022945A1 (en) 2001-04-05
CN1391466A (zh) 2003-01-15
EA200200414A1 (ru) 2002-12-26
NO20021475D0 (no) 2002-03-25
HK1045109A1 (zh) 2002-11-15
NO20021475L (no) 2002-04-16
BR0014351A (pt) 2002-06-11
PL354282A1 (en) 2003-12-29
AU7615000A (en) 2001-04-30
JP2003510269A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
US6437006B1 (en) Pharmaceutical carrier formulation
EP1185273B1 (en) Antifungal oral composition containing itraconazole and process for preparing same
EP2451438B1 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
US6221391B1 (en) Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
NL193267C (nl) Farmaceutisch preparaat in de vorm van een gelatinecapsule met een vulling die ranitidine-hydrochloride bevat.
JPH11512115A (ja) 経口投与用製剤組成物
US6352718B1 (en) Vasopressin antagonist formulation and process
JP5750278B2 (ja) カンデサルタンシレキセチルのカプセル充填用組成物
CA2388474A1 (en) Vasopressin antagonist formulation and process
CA2388471A1 (en) Pharmaceutical carrier formulation
EP3854384A1 (en) Pharmaceutical formulation comprising abiraterone acetate
EP0326103B1 (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
US6420358B1 (en) Vasopressin antagonist and diuretic combination
JPH04356420A (ja) チアミン・コバルト・クロロフィリン錯化合物含有組成物
SK11352003A3 (sk) Farmaceutický prostriedok
JP2005075804A (ja) メナテトレノン含有医薬組成物
WO2002060437A1 (en) Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
AU2002240206A1 (en) Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
WO2002013789A1 (en) Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
WO2014010008A1 (ja) カンデサルタンシレキセチルのカプセル充填用組成物
WO2001023366A2 (en) Vasopressin antagonist and diuretic combination

Legal Events

Date Code Title Description
FZDE Discontinued